news release
- company news
recently, our company on hypertension line, preferred drug yitai® perindopril tert-butylamine tablets and shangyao dongying ( jiangsu ) pharmaceutical co., ltd. to reach a strategic cooperation, access to the product exclusive national agency.
morewe have recently entered into a partnership with fuso teikoku qingdao co.,
morenanjing changao pharmaceutical science and technology co., limited received the supplemental approval for the consistency evaluation of calcium dobesilate tablets.
morec&o receives agency rights for clostridium butyricum tablets in some provinces
moreon september 17-19, 2020, the 83rd pharm china was held in guangzhou. pharm china is a professional event of great scale and influence in the field of preparations and grand health in china. the exhibition covers an area of 100,000 square meters, wit
morerecently, we have received the supplementary drug application approval from the nmpa for libeisi® - calcium dobesilate tablets (0.5g). the product has passed the generic drug consistency evaluation, indicating that it has reached the level of consist
more
address5/f, jihao building, 1086 shennan east road, luohu district, shenzhen
adverse drug reactions / event feedback hotline025-6816 1304
adverse drug reactions / event feedback mailgvp@changao.com
official wechat account mobile page